Cingulate Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Cingulate Stock Summary

Cingulate competes with Allarity Therapeutics, Lexaria Bioscience, Lixte Biotechnology, Kairos Pharma, and Synlogic. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficithyperactivity disorder. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Cingulate operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Cingulate Key Financial Ratios

Cingulate Key Balance Sheet Accounts

Cingulate Key Income Statement Accounts

Cingulate Key Cash Accounts

Cingulate Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cingulate's current stock value. Our valuation model uses many indicators to compare Cingulate value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cingulate competition to find correlations between indicators driving Cingulate's intrinsic value. More Info.Cingulate is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Cingulate's Return On Equity is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cingulate by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Cingulate Systematic Risk

Today, most investors in Cingulate Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cingulate's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cingulate growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Cingulate help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cingulate. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cingulate based on widely used predictive technical indicators. In general, we focus on analyzing Cingulate Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cingulate's daily price indicators and compare them against related drivers.

When running Cingulate's price analysis, check to measure Cingulate's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cingulate is operating at the current time. Most of Cingulate's value examination focuses on studying past and present price action to predict the probability of Cingulate's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cingulate's price. Additionally, you may evaluate how the addition of Cingulate to your portfolios can decrease your overall portfolio volatility.